Solid Biosciences (SLDB) EBIAT (2017 - 2024)
Historic EBIAT for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$42.6 million.
- Solid Biosciences' EBIAT fell 10948.07% to -$42.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$124.7 million, marking a year-over-year decrease of 2987.55%. This contributed to the annual value of -$124.7 million for FY2024, which is 2987.55% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' EBIAT is -$42.6 million, which was down 10948.07% from -$32.7 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' EBIAT ranged from a high of -$15.2 million in Q4 2022 and a low of -$42.6 million during Q4 2024
- For the 4-year period, Solid Biosciences' EBIAT averaged around -$24.6 million, with its median value being -$24.3 million (2024).
- As far as peak fluctuations go, Solid Biosciences' EBIAT skyrocketed by 3294.94% in 2020, and later crashed by 10948.07% in 2024.
- Over the past 4 years, Solid Biosciences' EBIAT (Quarter) stood at -$21.4 million in 2020, then increased by 29.08% to -$15.2 million in 2022, then tumbled by 34.22% to -$20.3 million in 2023, then plummeted by 109.48% to -$42.6 million in 2024.
- Its EBIAT stands at -$42.6 million for Q4 2024, versus -$32.7 million for Q3 2024 and -$25.1 million for Q2 2024.